BSE filing, BSE: 544611. Summary written from the filing by ALFA Finder's alert engine.
Mahamaya Lifesciences Ltd: key numbers
- Share price
- ₹171.00
- Market cap
- ₹400.2 Cr
- Revenue (annual)
- ₹329.3 Cr
- Net profit (annual)
- ₹16.72 Cr
- P/E (TTM)
- 23.9×Sector 34.5×
- Promoter holding
- 56.39%
- FII holding
- 2.66%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mahamaya Lifesciences Ltd
All →Mahamaya Lifesciences Business Update
Mahamaya Lifesciences announced the publication of an executive interview in AgroPages Magazine (2026 India Focus Issue), highlighting operational progress and strategic growth initiatives.
Mahamaya Lifesciences Management Change
Mahamaya Lifesciences Limited announced management changes including the appointment of Dr. Bhagirath Choudhary and re-appointment of two Independent Directors. The MD and Executive Director were also re-designated.
Mahamaya Lifesciences Annual General Meeting
Mahamaya Lifesciences Limited held its 24th Annual General Meeting on September 29, 2026. Shareholders considered resolutions including financial statement adoption, director re-appointments, and management re-designations.
Mahamaya Lifesciences Promoter Buying
Promoter Prashant Krishnamurthy acquired 7,200 equity shares of Mahamaya Lifesciences Ltd through open market purchases on BSE.
- Promoter stake change
- +0.02%
Mahamaya Lifesciences Annual Report
Mahamaya Lifesciences Limited has filed its Annual Report for the financial year 2025-26. The document details the company's financial and operational performance.
Mahamaya Lifesciences Annual General Meeting
Mahamaya Lifesciences Limited has issued the notice for its Annual General Meeting scheduled on September 29, 2026. The agenda includes financial adoption and various director appointments.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.